/
Adverse Event Collection Recommendations

Adverse Event Collection Recommendations

Project Scope 

This project team will create a White Paper with recommendations for Adverse Event Collection Instructions, with a focus on Phase 2-4 clinical trials. This project will build upon a paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices.

Project LeadsEmails

Aimee Basile, Otsuka Pharmaceutical

Aimee.Basile@otsuka-us.com

Mary Nilsson, Eli Lilly

nilsson_mary_e@lilly.com

Nicola Newton, PHUSE Project Assistant

nicky@phuse.global

CURRENT STATUS Q2 2024

  • Published recommendations in white paper 
Objectives & DeliverablesTimelines
Publish White PaperQ2 2024

Related content

Recommendations for Adverse Event Collection and Treatment Emergent Definition
Recommendations for Adverse Event Collection and Treatment Emergent Definition
More like this
Listings for Clinical Study Report
Listings for Clinical Study Report
More like this
Estimands in Oncology Safety Task Force
Estimands in Oncology Safety Task Force
More like this
Safety Analytics Webinar Series: Interdisciplinary Safety Evaluation for Learning and Decision-Making
Safety Analytics Webinar Series: Interdisciplinary Safety Evaluation for Learning and Decision-Making
More like this